Transdermal selegiline: The new generation of monoamine oxidase inhibitors

CNS Spectrums

Volumn 11, Issue 5, 2006, Pages 363-375

  Patkar, Ashwin A ^a   Pae, Chi Un ^a,b   Masand, Prakash S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CLORGYLINE; CORTICOSTEROID; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; HYPNOTIC AGENT; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; PARGYLINE; PETHIDINE; PHENELZINE; PHENYLPROPANOLAMINE; PLACEBO; PSEUDOEPHEDRINE; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG;

APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; ATAXIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIAPHORESIS; DIARRHEA; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEVER; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INSOMNIA; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; TERATOGENICITY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33646539184     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014498     Document Type: Review

References (88)

1. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull. 2002;36:124-138.
2. Ban TA. Pharmcotherapy of depression: a historical analysis. J Neural Transm. 2001;108:707-716.
3. Amsterdam JD, Chopra M. Monoamine oxidase inhibitors revisited. Psychiatr Ann. 2001;31:361-370.
4. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet. 1963;54:733-734.
5. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964;188:1108-1110.
6. Johnson AG. Monoamine oxidase inhibitors. Br Med J. 1968;2:433.
7. Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004;25:139-148.
8. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25:215-221.
9. Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol. 1987;45:111-118.
10. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27-34.
11. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226-247.
12. Johnston JP. Some observations upon a new inhibitor or monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1285-1297.
13. Lipper S, Murphy DL, Slater S, Buchsbaum MS. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62:123-128.
14. Chen DT, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacol. 1993;16(suppl 2):S63-S68.
15. Youdim MB. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl. 1995;386:5-7.
16. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53:5-11.
17. Lonnqvist J, Sintonen H, Syvalahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand. 1994;89:363-369.
18. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in braines of parkinsonian patients treated with I-deprenyl. Neurochem. 1986;46:1359-1365.
19. Glover V, Elsworth JD, Sandler M. Dopamine oxidation and its inhibition by I-deprenyl in man. J Neural Transm Suppl. 1980;16:163-172.
20. Birkmayer W. Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1983;95:103-105.
21. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245:519-522.
22. Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 1996;3:688-698.
23. Rohatagi S, Barrett JS, DeWitt KE, Morales RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 1997;18:567-584.
24. Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099-1104.
25. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of L-deprenyl. Arch Gen Psychiatry. 1989;46:45-50.
26. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EW, Quitkin FM. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989;25:63-67.
27. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607-615.
28. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
29. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1241-1255.
30. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375-382.
31. Tetrud JW, Koller WC. A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology. 2004;63(7 suppl 2):S2-S6.
32. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
33. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
34. Anderson MC, Hasan F, McCrodden JM, Tipton KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 1993;18:1145-9.
35. Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981;73:65-74.
36. Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology. 2004;63(7 suppl 2):S32-35.
37. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31-56.
38. McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Diet Assoc. 1986;86:1059-1064.
39. Wilkosz MF. Transdermal Drug Delivery. Part 1: Current Status. US Pharmacist [serial online]. 2003:28. Available at: http://www.uspharmacist.com/ index. asp?show=article&page=8_1061.htm. Accessed November 30, 2005.
40. Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG. L-deprenyl alters the survival of adult murine facial motoneurons after axotomy increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res. 1994;38:64-74.
41. Rohatagi S, Barrett JS, McDonald LJ, Morris EM, Darnow J, DiSanto AR. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res. 1997;14:50-55.
42. EMSAM® selegiline transdermal system new drug application 21,336/21,708. Food and Drug Administriation Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4186B2_01_01_Somerset- EMSAM.pdf. Accessed October 26, 2005.
43. Krishnan R. Advances in psychopharmacology: MAOIs. Scientific report session. Abstract presented at: the 157th Annual Meeting of the American Psychiatric Association: May 1-6, 2004: New York, NY
44. Wagner GC, Walsh SL. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. Int J Dev Neurosci. 1991;9:171-174.
45. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem. 1994;62:380-383.
46. Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav. 1999;63:501-506.
47. EMSAM [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2006.
48. Barrett JS, Hochadel TJ, Morales RJ, et al. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J Clin Pharmacol. 1997;37:238-247.
49. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989;46:344-351.
50. Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther. 1992;52:286-291.
51. VanDenBerg CM, Blob LF, Gerrick G, et al. Blood pressure response produced by a tyramine-enriched meal following multiple does administration of 20cm2/20mg selegiline transdermal system (STS) in health male volunteers. Abstract presented at: Annual Meeting of the New Clinical Drug Evaluation Unit. May 30-June 2, 2000: Boca Raton, FL
52. Mccabe BJ, Gurley BJ. Transdermal selegiline and dietary tyramine: is there a concern? J Am Diet Assoc. 2003;103(9 suppl 1):A25.
53. Shulman KI, Walker SE. A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors. Psychiatr Ann. 2001;31:378-384.
54. Azzaro AJ, Blob LF, Kemper EM, Sharoky M, VanDenBerg CM. Pressor effects of oral tyramine and over-the-counter (OTC) sympathomimetic amines following steady-state transdermal administration of selegiline to healthy volunteers. In: Scientific Abstracts of the 2000 Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn; Abstract 268.
55. Blob LF, VanDenBerg CM, Kemper EM, et al. Safety of selegiline transdermal system: concomitant administration of pseudoephedrine, a sympathomimetic amine. Abstract presented at: Annual Meeting of the New Clinical Drug Evaluation Unit. May 28-31, 2001: Phoenix, Ariz.
56. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-13.
57. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997;247:113-119.
58. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48:1070-1077.
59. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869-1875.
60. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208-214.
61. Guelfi JD, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord. 2000;58:201-209.
62. Moonsammy G, Blob LF, Sharoky M, VanDenBerg CM, Azzaro AJ. Safety of selegiline transdermal system in long-term prevention of relapse of depression. Abstract presented at: the Annual Meeting of the New Clinical Drug Evaluation Unit; May 27-30, 2003: Boca Raton, FL.
63. Pauporte M, Azzaro AJ, Moonsammy G, Maibach H. Selegiline Transdermal System (STS): Assessment of dermal safety in human. J Toxicol. 2004;23:179-187.
64. Robinson DS, Campbell IC, Walker M, Statham NJ, Lovenberg W, Murphy DL Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain. Neuropharmacology. 1979;18:771-776.
65. Campbell IC, Shiling DJ, Lipper S, Slater S, Murphy DL. A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. J Psychiatr Res. 1979;15:77-84.
66. Blier P, De Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat-central nervous system. J Pharmacol Exp Ther. 1986;237:987-994.
67. Stamford JA, Davidson C, McLaughlin DP, Hopwood SE. Control of dorsal raphe 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? Trends Neurosci. 2000;23:459-465.
68. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res. 1992;38:171-297.
69. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of L-deprenyl. Curr Med Chem. 2004;11:2017-2031.
70. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8:365-370.
71. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry. 1998;59(suppl 18):5-9.
72. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry. 1995;152:31-36.
73. Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord. 2002;72:125-138.
74. Henkel V, Mergl R, Allgaier AK, Kohnen R, Moller HJ, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141:89-101.
75. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157:344-350.
76. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand. 1988;78:676-683.
77. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14:3-20.
78. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression-a retrospective study. J Affect Disord. 2005;89:183-188.
79. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150:118-123.
80. Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehranidoost M, Mesgarpour B, Soori H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. J Child Adoles Psychopharmacol. 2004;14:418-425.
81. Mechcatie E. Transdermal MAO inhibitor patch effective for ADHD. Clinical Psychiatry News. June 2003:18.
82. Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl). 2004;172:31-40.
83. Bartzokis G, Beckson M, Newton T, et al. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology. 1999;20:582-590.
84. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403-1407.
85. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53:136-143.
86. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis. 1996;184:295-301.
87. Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry. 1999;40:148-150.
88. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current pychiatric practice. J Psychiatr Pract 2004;10:239-248.